ECHO Trial Highlights Acalabrutinib’s Promise in Mantle Cell Lymphoma Treatment
Dr. Martin Dreyling presents results from the phase 3 ECHO trial at ASH 2024, evaluating the combination of acalabrutinib with bendamustine and rituximab in treating mantle cell lymphoma. This study demonstrated a significant improvement in PFS with a hazard ratio of 0.7 and a 10-15% increase in PFS rates. Although OS benefits were less clear due to the impact of the COVID-19 pandemic, the findings confirm that acalabrutinib improves outcomes, particularly for high-risk patients.
